Photo taken from Giuseppe Curigliano/LinkedIn
Jun 5, 2024, 15:33
Giuseppe Curigliano: Excited that the DESTINY-06 trial was presented at ASCO2024
Giuseppe Curigliano shared on LinkedIn:
“Excited to share that the DESTINY-06 trial was presented at ASCO2024 and received fantastic feedback from our outstanding audience!
A huge thank you to everyone who attended and supported our work in advancing cancer treatment.
Together, we’re making strides in oncology!”
Source: Giuseppe Curigliano/LinkedIn
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology.
He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14